Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GBS Inc. stock logo
GBS
GBS
$1.29
-0.8%
$1.73
$0.36
$2.89
$19.21M1.32955,325 shs52,183 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.91
+1.1%
$1.83
$1.42
$13.44
$70.05M1.84578,346 shs219,069 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.45
+5.6%
$2.77
$1.87
$3.80
$75.06M0.7435,074 shs64,653 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.45
-6.5%
$4.69
$3.41
$9.33
$73.40M1.11311,328 shs112,855 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GBS Inc. stock logo
GBS
GBS
0.00%+6.61%-14.57%-8.51%-52.04%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+1.06%+3.24%+10.40%-5.91%-83.39%
InspireMD, Inc. stock logo
NSPR
InspireMD
+5.60%-3.92%-9.26%+0.82%+26.94%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-6.51%-3.89%-6.71%-33.58%+31.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GBS Inc. stock logo
GBS
GBS
N/AN/AN/AN/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.3738 of 5 stars
3.31.00.04.31.60.01.3
InspireMD, Inc. stock logo
NSPR
InspireMD
2.5723 of 5 stars
3.50.00.00.02.82.50.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.1372 of 5 stars
3.62.00.00.02.00.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GBS Inc. stock logo
GBS
GBS
0.00
N/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$12.20538.74% Upside
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.7593.88% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$13.00192.13% Upside

Current Analyst Ratings Breakdown

Latest GBS, SRTS, NSPR, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
3/11/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $13.00
2/10/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$11.00 ➝ $12.00
1/31/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GBS Inc. stock logo
GBS
GBS
$440K43.65N/AN/A$0.44 per share2.93
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$217.76K321.67N/AN/A$5.16 per share0.37
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.01M10.71N/AN/A$1.83 per share1.34
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.76$0.05 per share96.29$2.98 per share1.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GBS Inc. stock logo
GBS
GBS
-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.99N/AN/AN/AN/A-118.17%-83.47%5/12/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.78N/AN/AN/A-413.96%-69.42%-57.68%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.4011.1319.35N/A15.90%12.60%11.38%5/8/2025 (Estimated)

Latest GBS, SRTS, NSPR, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74N/AN/AN/A$0.01 millionN/A
5/8/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04N/AN/AN/A$7.23 millionN/A
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
2/5/2025Q4 2024
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.10$0.09-$0.01$0.09$10.31 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GBS Inc. stock logo
GBS
GBS
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GBS Inc. stock logo
GBS
GBS
N/A
2.33
2.33
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89

Institutional Ownership

CompanyInstitutional Ownership
GBS Inc. stock logo
GBS
GBS
2.79%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
GBS Inc. stock logo
GBS
GBS
0.27%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
InspireMD, Inc. stock logo
NSPR
InspireMD
29.72%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
9.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
GBS Inc. stock logo
GBS
GBS
714.89 million14.85 millionNot Optionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5030.64 million18.33 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.50 million14.85 millionOptionable

Recent News About These Companies

A Closer Look At Sensus Healthcare's Earnings
Sensus Healthcare price target lowered to $13 from $18 at Lake Street
Lake Street Remains a Buy on Sensus Healthcare (SRTS)
Sensus Healthcare participates in a conference call with Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBS stock logo

GBS NYSE:GBS

$1.29 -0.01 (-0.77%)
As of 04/25/2025

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.91 +0.02 (+1.06%)
Closing price 04/29/2025 04:00 PM Eastern
Extended Trading
$1.90 0.00 (-0.26%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.45 +0.13 (+5.60%)
Closing price 04/29/2025 03:56 PM Eastern
Extended Trading
$2.42 -0.03 (-1.02%)
As of 04/29/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.45 -0.31 (-6.51%)
Closing price 04/29/2025 04:00 PM Eastern
Extended Trading
$4.50 +0.04 (+1.01%)
As of 04/29/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.